P
Pierre Charles
Researcher at Paris Descartes University
Publications - 43
Citations - 1963
Pierre Charles is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Granulomatosis with polyangiitis & Rituximab. The author has an hindex of 17, co-authored 37 publications receiving 1482 citations. Previous affiliations of Pierre Charles include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Single-Center Trials Show Larger Treatment Effects Than Multicenter Trials: Evidence From a Meta-epidemiologic Study
TL;DR: A meta-epidemiologic study to evaluate whether estimates of treatment effect differ between single-center and multicenter randomized, controlled trials (RCTs), finding that single- center RCTs showed larger treatment effects than did multicenter R CTs, a finding that was consistent in all sensitivity analyses.
Journal ArticleDOI
Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study
Amélie Yavchitz,Isabelle Boutron,Isabelle Boutron,Aïda Bafeta,Aïda Bafeta,Ibrahim Marroun,Pierre Charles,Jean Mantz,Philippe Ravaud,Philippe Ravaud +9 more
TL;DR: A study examines the factors associated with “spin” (specific reporting strategies, intentional or unintentional, that emphasize the beneficial effect of treatments) in press releases of clinical trials.
Journal ArticleDOI
Reporting of sample size calculation in randomised controlled trials: review
TL;DR: Quality of reporting of sample size calculation is still inadequately reported, often erroneous, and based on assumptions that are frequently inaccurate, which raises questions about how sample size is calculated in randomised controlled trials.
Journal ArticleDOI
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Pierre Charles,Benjamin Terrier,Elodie Perrodeau,Pascal Cohen,Stanislas Faguer,Antoine Huart,Mohamed Hamidou,Christian Agard,Bernard Bonnotte,Maxime Samson,Alexandre Karras,Noémie Jourde-Chiche,François Lifermann,P. Gobert,Catherine Hanrotel-Saliou,Pascal Godmer,Nicolas Martin-Silva,Grégory Pugnet,Marie Matignon,Olivier Aumaître,Jean-François Viallard,François Maurier,Nadine Meaux-Ruault,Sophie Rivière,Jean Sibilia,Xavier Puéchal,Philippe Ravaud,Luc Mouthon,Loïc Guillevin +28 more
TL;DR: AAV relapse rates did not differ significantly between individually tailored and fixed-schedule rituximab regimens, and individually tailored-arm patients received fewer ritUXimab infusions.
Journal ArticleDOI
Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients
Pierre Charles,Antoine Néel,Nathalie Tieulie,Arnaud Hot,Grégory Pugnet,Olivier Decaux,Isabelle Marie,Mehdi Khellaf,Jean-Emmanuel Kahn,Alexandre Karras,Jean-Marc Ziza,Christophe Deligny,Colas Tcherakian,Loïc Guillevin +13 more
TL;DR: Rituximab was able to induce AAV remission and seemed to maintain remission better than other agents, but caution is needed concerning its safety, especially regarding bacterial infections, in this population of patients.